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SUMMARY
Dmp1 (Dmtf1) is activated by oncogenic Ras-Raf signaling and induces cell-cycle arrest in an Arf,
p53-dependent fashion. The survival of K-rasLA mice was shortened by 15 weeks in both Dmp1+/
and Dmp1/ backgrounds, the lung tumors of which showed significantly decreased frequency of
p53 mutations compared to Dmp1+/+. Approximately 40% of K-rasLA lung tumors from Dmp1+/+
mice lost one allele of theDmp1 gene, suggesting the primary involvement ofDmp1 in K-ras-induced
tumorigenesis. Loss of heterozygosity (LOH) of the hDMP1 gene was detectable in 35% of human
lung carcinomas, which was found in mutually exclusive fashion with LOH of INK4a/ARF or that of
P53. Thus, DMP1 is a pivotal tumor suppressor for both human and murine lung cancers.INTRODUCTION
Lung cancer is the leading cause of cancer deaths in the
world, and accounts for more solid tumor deaths than
any other carcinomas. More than 170,000 new cases
are diagnosed each year in the United States alone, of
which 160,000 will eventually die, representing 30% of
all cancer deaths (Jemal et al., 2006). Lung cancer can be
categorized into two major histopathological groups: non-
small-cell lung cancer (NSCLC) (Spira and Ettinger, 2004;
Moran, 2006) and small-cell lung cancer (SCLC) (Schiller,
2001), the latter of which show neuroendocrine features.
Approximately 80% of lung cancers are NSCLC, and
they are subcategorized into adenocarcinomas, squa-
mous cell carcinomas, adenosquamous carcinomas, andClarge-cell carcinomas (Travis, 2002). SCLC and NSCLC
show major differences in histopathologic characteristics
that can be explained by the distinct patterns of genetic
alterations found in both tumor classes (Zochbauer-
Muller et al., 2002). For instance, the K-Ras gene is mu-
tated in 20%–30% of NSCLC while its mutation is rare
in SCLC; Rb inactivation is found in 90% of SCLC while
p16INK4a is inactivated by deletion and/or promoter hyper-
methylation in 50% of NSCLC (for reviews see Fong
et al., 2003; Meuwissen and Berns, 2005; Wistuba et al.,
2001). Among dozens of the murine models of human
lung cancer, the K-rasLA/+ (K-rasLA1/+, K-rasLA2/+) mouse
model is one of the most sophisticated ones that mimic
human NSCLC (Johnson et al., 2001). In this model, the
K-ras gene is controlled by its own promoter and isSIGNIFICANCE
Dmp1 (Dmtf1) is activated by oncogenic Ras signaling and shows its tumor suppressor activity through the acti-
vation of the Arf-p53 pathway in mice. Here, we show thatDmp1 deletion cooperates with oncogenicK-ras to form
lung cancers in vivo, and those tumors from Dmp1-knockout mice have significantly less frequent p53 mutations.
Importantly, deletion of one allele ofDmp1was found in 30%–40% of K-ras-induced murine lung tumors as well as
in human non-small cell lung carcinomas, in which ARF and/or P53 remained intact. The present work provides
evidence that hDMP1 is a physiological regulator of the ARF-P53 pathway in humans and is primarily involved
in pulmonary carcinogenesis.ancer Cell 12, 381–394, October 2007 ª2007 Elsevier Inc. 381
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in the whole animal. Abnormality of the P53 gene is one
of the most common events in human lung cancers
(Toyooka et al., 2003), and accordingly,K-rasLA/+ lung car-
cinogenesis was strikingly accelerated in mice of both
p53+/ and p53/ backgrounds (Johnson et al., 2001).
The activity of p53 is positively regulated by p19Arf
(p14ARF in humans) in response to oncogenic stress
(Lowe and Sherr, 2003; Sherr 2001, 2006). p19Arf is an al-
ternative reading frame gene product generated from the
Ink4a/Arf locus that also encodes the cyclin-dependent ki-
nase inhibitor p16Ink4a. p19Arf directly binds to Mdm2,
thereby stabilizing and activating p53, whereas p16Ink4a
binds to cyclin-dependent kinase 4 to inhibit Rb phos-
phorylation (Kim and Sharpless, 2006; Lowe and Sherr,
2003; Sherr, 2001). Since this single genetic locus en-
codes two independent tumor suppressor proteins that
regulate the p53 and the Rb pathways, it is very frequently
disrupted in human cancer (Ruas and Peters, 1998). Arf is
induced by potentially harmful growth-promoting signals
stemming from overexpression of various oncoproteins
(Lowe and Sherr, 2003; Sherr, 2001). This Arf induction
forces early-stage cancer cells to undergo p53-depen-
dent and p53-independent cell-cycle arrest or apoptosis,
providing a powerful mode of tumor suppression. The Arf
promoter monitors latent oncogenic signals in vivo (Zindy
et al., 2003), and thus, Arf null mice are highly prone to
spontaneous tumor development (Kamijo et al., 1999).
There is a body of evidence showing the p53-independent
functions of Arf (reviewed in Sherr, 2006). In human lung
cancers, p14ARF is inactivated in 65% of SCLC, while
the gene is deleted in 20% of NSCLC. Promoter hyper-
methylation ofARF has been reported in10% of NSCLC,
but is less frequent than that of p16INK4a (40%) on the
same locus (Meuwissen and Berns, 2005). The Arf tran-
scription is negatively regulated by overexpression of
nuclear proteins such as Bmi1, Twist, Tbx-2/3, and Po-
kemon, and overexpression of these proteins have been
reported in human cancers (Brummelkamp et al., 2001;
Maeda et al., 2005; Maestro et al., 1999; Jacobs et al.,
1999, 2000; Yang et al., 2004).
Among known Arf activators, Dmp1 (cyclin D binding
myb-like protein-1; also called Dmtf1, cyclin D binding
myb-like transcription factor 1) is a unique tumor suppres-
sor (Hirai and Sherr, 1996; Inoue and Sherr, 1998; for re-
view see Inoue et al., 2007). Dmp1 was originally isolated
in a yeast two-hybrid screen of a murine T-lymphocyte
library with cyclin D2 as bait (Hirai and Sherr, 1996). Al-
though Dmp1 is structurally related to Myb family proteins,
it binds to nonameric CCCG(G/T)ATG(T/C) DNA consen-
sus sequences, a subset of which is also recognized
by proteins of the Ets family. Importantly, Dmp1 directly
binds to the Arf promoter to activate its expression,
thereby inducing p53-dependent cell-cycle arrest (Inoue
et al., 1999). Dmp1 null mice are prone to spontaneous
tumor development, which was accelerated when the
animals were neonatally treated with ionizing radiation or
dimethylbenzanthracene (Inoue et al., 2000, 2001). Lung
adenomas/adenocarcinomas were the most common tu-382 Cancer Cell 12, 381–394, October 2007 ª2007 Elsevier Incmors found in Dmp1-knockout mice. The retention and
expression of the wild-type Dmp1 allele in tumors arising
in heterozygotes indicated that Dmp1 is haplo-insufficient
for tumor suppression (Inoue et al., 2001; for review see
Quon and Berns, 2001). The low frequency of Arf deletion
and p53 mutation in tumors from Dmp1-knockout mice
suggested that Dmp1 is a physiological regulator of the
Arf-p53 pathway in vivo (Inoue et al., 2001). Information
about the signaling cascades that regulate Dmp1 has
been accumulating. The Dmp1 promoter is activated by
the oncogenic Ras-Raf-MEK-ERK-Jun pathway, and the
induction of Arf by Ras is Dmp1 dependent (Sreeramaneni
et al., 2005). On the other hand, the Dmp1 promoter is
repressed by overexpression of E2Fs and also by physio-
logical mitogenic signaling. Thus, Dmp1 is a marker of
cells that have exited from the cell cycle (Mallakin et al.,
2006). Our recent study shows that the Dmp1 promoter
is repressed by genotoxic stimuli that activate NF-kB
(Taneja et al., 2007).
In striking contrast to the accumulating information on
murine Dmp1, very little is known about the involvement
of human DMP1 (hDMP1; hDMTF1) in cancer. The hDMP1
protein has very high structural homology with its murine
counterpart (95% identity with murine Dmp1 at the pro-
tein level). One allele of the genes at the hDMP1 locus
was reportedly deleted in all the leukemic cells with chro-
mosome 7q abnormalities regardless of the detailed kar-
yotype at 7q, suggesting that one allelic loss of hDMP1
could contribute to 7q malignancies that are refractory
to conventional chemotherapy (Bodner et al., 1999). It
has been reported that the hDMP1 locus encodes at least
three splicing variants, hDMP1a, b, and g (Tschan et al.,
2003). The full-length hDMP1a gene corresponds to the
murine Dmp1 gene that positively regulates the p19Arf-
p53 pathway (Inoue et al., 1999; Tschan et al., 2003). By
contrast, the hDMP1b and g proteins do not bind to
DNA and hDMP1b has dominant-negative effect on
hDMP1a when it is overexpressed (Tschan et al., 2003).
Although Dmp1 plays critical roles as a mediator of ras
signaling toArf induction in cultured cells, the role of Dmp1
in ras signaling has not been demonstrated in vivo. This
study was conducted to demonstrate the collaborative ef-
fects of Dmp1 inactivation and K-ras activation in pulmo-
nary carcinogenesis. We found that one allele of Dmp1
was deleted in a significant percentage of lung tumors
from Dmp1+/+; K-rasLA mice, showing the primary role of
Dmp1 in murine lung cancer. We also analyzed 51 human
NSCLC samples for hDMP1, INK4a/ARF, and P53 and
show that LOH of the hDMP1 gene is frequently found in
NSCLC, especially those which retain an intact INK4a/
ARF and/or P53 locus.
RESULTS
K-rasLA-Induced Tumorigenesis Is Significantly
Accelerated in both Dmp1/ and Dmp1+/ Mice
In order to investigate the cooperation of Dmp1-inactiva-
tion and K-ras activation in vivo, we backcrossed Dmp1-
knockout mice for six generations with a C57BL/6 male.
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Deletion of DMP1 in Lung CancerFigure 1. Tumor-free Survival in Cohorts
of Dmp1+/+, Dmp1+/, and Dmp1/;
K-rasLA2/+ Mice and Dmp1+/+, Dmp1+/,
and Dmp1/;K-rasLA1/+ Mice
(A) Statistically significant difference in survival
was found between Dmp1+/+ versus Dmp1+/;
K-rasLA2/+ (p < 0.005) and Dmp1+/+ versus
Dmp1/;K-rasLA2/+ mice (p < 0.005). There
were no significant differences in survival be-
tween Dmp1+/ versus Dmp1/;K-rasLA2/+
(p = 0.38).
(B) Significant difference of survival was found
between Dmp1+/+ versus Dmp1/;K-rasLA1/+
(p < 0.001) and Dmp1+/+ versus Dmp1+/;
K-rasLA1/+ mice (p = 0.001), but not between
Dmp1+/ versus Dmp1/;K-rasLA1/+ (p =
0.13).
(C) Retention of the Dmp1 wild-type allele in
lung tumors from Dmp1+/;K-rasLA/+ mice as
examined by genomic DNA PCR.
(D) Expression of the Dmp1 mRNA in lung tu-
mors from Dmp1+/+, Dmp1+/, and Dmp1/;
K-rasLA/+ mice. Real-time PCR was conducted
to quantitate the Dmp1 mRNA expression in
K-rasLA/+ lung tumors. Black bars show the
average level of Dmp1 expression in the lung
of each genotype. Gray bars are the samples
that showed higher level of Dmp1 expression
in K-rasLA lung tumors than in their normal
lung controls. The means ± SD for three exper-
iments are shown.
(E) Well-differentiated lung adenocarcinoma
found in a Dmp1+/;K-rasLA1/+ mouse; H&E
stain.
(F) Detection of the Dmp1 protein in the nuclei
of Dmp1+/;K-rasLA1/+ mouse tumor cells with
the Dmp1-specific antibody, RAX.
(G) Negative staining of the lung tumor section
of Dmp1/;K-rasLA1/+ mouse with RAX anti-
body. Scale bar in (E), (F), and (G) is 100 mm.and then crossed the Dmp1+/ mice with K-rasLA2/+ or
K-rasLA1/+ mice (Johnson et al., 2001). The average survival
of wild-type K-rasLA mice was 10–15 weeks longer in our
C57BL/6 strain than in the original report due to the differ-
ence of the genetic background. K-rasLA2/+-induced tu-
morigenesis was greatly accelerated in both Dmp1/
and Dmp1+/ mice with no differences between groups
of Dmp1/ and Dmp1+/ (Figure 1A; mean survival 21
weeks inDmp1/,Dmp1+/ versus 35 weeks inDmp1+/+,
p < 0.005 in both cases).K-rasLA1/+-induced tumor forma-
tion was also accelerated in both Dmp1/ and Dmp1+/
backgrounds (mean survival 36 weeks in Dmp1/ [p <
0.001], 41 weeks in Dmp1+/ [p = 0.001], and 55 weeks
for Dmp1+/+) (Figure 1B). Although the average survival
was slightly shorter in Dmp1/;K-rasLA1/+ mice than in
Dmp1+/;K-rasLA1/+ mice, there was no statistically signif-
icant differences between these two cohorts (p = 0.13). All
of theK-rasLA mice generated lung tumors (adenomas and
adenocarcinomas) regardless of theDmp1 genotype, with
minor differences in the incidence of thymic lymphomasC(30%) and tail papillomas (20%–30%) (see Figure S1A
in the Supplemental Data available with this article online).
Some of the Dmp1+/, Dmp1/;K-rasLA/+ mice devel-
oped other types of tumors than lung carcinomas, thymus
lymphomas, or papillomas. They included a case of chol-
angiocarcinoma, osteosarcoma, neurofibrosarcoma, and
ovarian tumor (Figure S1; a picture of cholangiocarcinoma
is shown in Figure 2E). Lung tumors from Dmp1+/;
K-rasLA1/+ and Dmp1+/;K-rasLA2/+ mice retained the wild-
type Dmp1 allele when examined by genomic DNA PCR
(Figure 1C). The levels of Dmp1 mRNA expression was
2–5 times higher in 8 of 11 lung tumors from Dmp1+/+;
K-rasLA mice than in normal lungs, suggesting the activa-
tion of the endogenous Dmp1 promoter by oncogenic
K-ras (Figure 1D, middle left panel, gray bars). However,
the Dmp1 mRNA levels were at comparable levels in 3
of 11Dmp1+/+;K-rasLA lung tumors, suggesting the disrup-
tion of the ras-Dmp1 signaling pathway (Figure 1D, middle
left panel, white bars). Likewise, the level of Dmp1 mRNA
was 2–4 times higher in 6 of 11 Dmp1+/;K-rasLAancer Cell 12, 381–394, October 2007 ª2007 Elsevier Inc. 383
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Tumors Found in K-rasLA/+ Mice
(A) Multiple lung adenomas and adenocarci-
nomas in a Dmp1+/+;K-rasLA1/+ mouse (42-
week-old).
(B) Advanced lung adenocarcinoma in
a Dmp1+/;K-rasLA1/+ mouse (39-week-old).
(C) Disseminated lung adenocarcinoma in
a Dmp1/;K-rasLA1/+ mouse (38-week-old).
(D) Leg metastasis of lung adenocarcinoma in
a Dmp1+/;K-rasLA1/+ mouse (40-week-old).
(E) Cholangiocarcinoma of the liver in a
Dmp1+/;K-rasLA1/+ mouse (40-week-old).
(F) Lung nodule number and size (mean ± SEM)
in K-rasLA mice. Ranges were compared with
unpaired Student’s t tests.
(G) Well-differentiated adenocarcinoma found
in a Dmp1+/+;K-rasLA2/+ mouse.
(H) Poorly differentiated adenocarcinoma in
a Dmp1+/;K-rasLA2/+ mouse. The tumor cells
are very pleomorphic and are invading into
blood vessels.
(I) Intrabronchial invasion of a Dmp1/;
K-rasLA2/+ lung carcinoma.
(J) Liver metastasis of lung adenocarcinoma in
a Dmp1+/;K-rasLA2/+ mouse.
Scale bar in (G), (H), (I), and (J) is 100 mm.lung tumors than in Dmp1+/ lungs while they were at the
same or lower levels in 5 of 11 cases (Figure 1D, middle
right panel). Nucleotide sequencing of Dmp1 RT-PCR
products from five lung tumors from different mice iden-
tified no mutation of Dmp1 in the DNA-binding do-
main (data not shown). Immunohistochemical staining of
Dmp1+/ lung carcinomas with Dmp1-specific antibody
(RAX; Mallakin et al., 2006) showed that Dmp1 protein is
expressed in lung tumor cells from a Dmp1+/;K-rasLA
mice (Figures 1E–1G). These data indicate haploid insuffi-
ciency of Dmp1 in suppressing K-ras-induced tumor for-
mation.
Biological Features of Dmp1+/ and Dmp1/
Lung Tumors
All K-rasLA mice developed multifocal lung tumors when
they showed signs of distress and were sacrificed, regard-
less of the Dmp1 genotype (Figures 2A–2C; Figure S1).
Lung carcinomas were found in more than half of
Dmp1+/ or Dmp1/;K-rasLA mice and were significantly
larger than those found in Dmp1+/+ mice of the same age
(Figures 2A–2C; all the mice were 40 weeks old). It was
common to find nearly entire replacement of the lung by
tumors in Dmp1+/ or Dmp1/ lung tumors (Figures 2B
and 2C). The number of lung tumor nodules significantly
increased in both Dmp1+/ and Dmp1/ mice when the384 Cancer Cell 12, 381–394, October 2007 ª2007 Elsevier Inc.mice became sick and sacrificed (p = 0.008 and p =
0.016, respectively; Figure 2F). Also a trend toward in-
creased nodule size was seen in both Dmp1+/ and
Dmp1/ mice; however, the difference was not statisti-
cally significant due to relatively large variation of tumor
size (p = 0.093 and p = 0.077, respectively). Two of 36
Dmp1+/;K-rasLA2/+ mice and 2 of 38 Dmp1+/;K-rasLA1/+
developed macroscopically recognized distant metasta-
ses (three liver/intra-abdominal metastases and one leg
metastasis) of their lung tumors (Figure 2D, leg metastasis;
Figure 2J, liver metastasis), while none of 50 Dmp1+/+;
K-rasLA/+ mice showed macroscopic metastatic lesions.
The leg or abdominal tumors were negative for markers
of carcinoid tumors (chromogranin, synaptophysin) but
were positive for a marker for the lung surfactant protein
C (Figure S2), indicating that they were metastases of
the lung adenocarcinomas. When examined under the
light microscope, tumors from Dmp1+/+;K-rasLA mice
were adenomas or well-differentiated adenocarcinomas
that mimic human papillary adenocarcinomas (20%
when the largest lung tumor nodules were studied)
(Figure 2G). Approximately 50% of the largest lung tumors
from Dmp1+/ or Dmp1/ mice were well, moderately, or
poorly differentiated adenocarcinomas, many of which
showed signs of intravascular (Figure 2H) or intrabronchial
invasion (Figure 2I). There was a trend of increased
Cancer Cell
Deletion of DMP1 in Lung CancerFigure 3. Analysis of the Arf-Mdm2-p53
Pathway in K-rasLA/+ Lung Tumors
(A) Western blotting of lung tumors for p53,
Mdm2, p19Arf, and p16Ink4a. Tumor cells were
resected from the center of well-circumscribed
lung carcinomas under the light microscope
and proteins were extracted. The control cell
lysates were obtained from spontaneously im-
mortalized p53 mutant MEFs for p53, p19Arf,
p16Ink4a, and Actin; dm3T3 cells for Mdm2.
The p53 mutations were detected in 4 of 11
Dmp1+/+;K-rasLA/+ mice (36%) while they
were not found in the Dmp1+/ and Dmp1/;
K-rasLA/+ lung tumors.
(B) Detection of the p19Arf Exon1b genomic
DNA by semiquantitative-PCR. The Arf gene
was not homozygously deleted in K-rasLA
lung tumors regardless of the Dmp1 genotype.
(C) Quantification of the Dmp1 genomic DNA
by real-time PCR. The black bars show the rel-
ative copy number of the Dmp1 genomic DNA
in Dmp1+/+, Dmp1+/, and Dmp1/ mice tails,
with b-actin as an internal control (mean ±
SEM). TheDmp1 locus is deleted in 5 of 12 ran-
domly chosen lung tumors from Dmp1+/+;
K-rasLA/+ mice. The Dmp1 gene was hemizy-
gously deleted in 5 of 8 cases of K-rasLA/+
lung tumors with wild-type p53 (465, 381,
154, 395, and 205).
(D) Quantification of the Dmp1 genomic DNA in
lung tumors from p53+/ or p53/; K-rasLA
mice (mean ± SEM). The Dmp1 gene was not
deleted in any one of these 14 lung tumors
from p53-knockout mice.frequency of intravascular or intrabronchial invasion in
Dmp1+/ (8/28, 28.6%) or Dmp1/ (6/16, 37.5%);K-rasLA
lung tumors than in Dmp1+/+;K-rasLA lung tumors (4/22,
18.2%) when they became sick and sacrificed. However,
the difference was not statistically different (p = 0.244 for
Dmp1+/ versus Dmp1+/+ and p = 0.102 for Dmp1/ ver-
sus Dmp1+/+, respectively) possibly because Dmp1+/+;
K-rasLA mice lived 14–19 weeks longer than Dmp1+/ or
Dmp1/;K-rasLA mice (Figures 1A and 1B), and by that
time, many of Dmp1+/+;K-rasLA lung tumors have corrup-
ted the Dmp1-p53 pathway (see the following molecular
analyses).
p53 Mutation Is Rare in Lung Tumors from
Dmp1+/ or Dmp1/;K-rasLA/+ Mice
Previous work had suggested that Dmp1 is a physiologi-
cal regulator of the Arf-Mdm2-p53 tumor surveillance
pathway in Em-Myc lympholeukemias (Inoue et al., 2001).
Thus, we studied the frequency of p53 mutations, Mdm2Coverexpression, and Ink4a/Arf deletions in Dmp1 wild-
type K-rasLA lung carcinomas. p53 was highly (356, 59,
and 844) or moderately (208) overexpressed in 4 of 11
Dmp1+/+ lung tumors (36%) randomly chosen for analysis
(Figure 3A). These patterns of p53 protein expression are
typical of mutant forms of p53, which neither transcription-
ally activate Mdm2 to trigger p53 destruction (Haupt et al.,
1997; Kubbutat et al., 1997) nor repress Arf transcription
(Stott et al., 1998). Cloning and sequencing of the cDNA
for p53 demonstrated the existence of mutations within
the DNA-binding domain in all the four lung cancer sam-
ples that overexpressed p53 (data not shown). Three
Dmp1+/+;K-rasLA/+ lung tumors expressed significant
levels of p19Arf (356, 59, 844), suggesting the disruption
of the p53-Arf feedback loop in these tumors. On the other
hand, none of the Dmp1+/ or Dmp1/;K-rasLA/+ lung tu-
mors showed high levels of expression of p53, suggesting
that the vast majority of the p53 protein expressed in
Dmp1-knockout tumors was wild-type (Figure 3A, topancer Cell 12, 381–394, October 2007 ª2007 Elsevier Inc. 385
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Dmp1/;K-rasLA/+ lung tumors, consistent with the wild-
type p53 expression in these tumors (Figure 3A, third
panels). Mdm2 was not overexpressed in any of the
K-rasLA lung tumors compared with the murine cell line
that overexpresses Mdm2 (Figure 3A, second panels).
None of the p53, Arf, or Ink4a genes showed biallelic de-
letion in any of the lung tumors examined, regardless of
their Dmp1 status as studied by semiquantitative PCR
analyses (representative data for Arf Exon 1b are shown
in Figure 3B; for p16Ink4a and p53, data not shown). How-
ever, Arf was hemizygously deleted in 25% of K-rasLA
lung tumors irrespective of the Dmp1 genotype as studied
by real-time PCR (Figure S3A). The Ink4a/Arf modulators,
Bmi1, Twist, Tbx2/3, and Pokemon have been reported to
downregulate p19Arf levels and contribute to tumor forma-
tion. However, none of these proteins was overexpressed
in K-rasLA lung tumors in comparison to 3T3 cells as ex-
amined by western blotting with specific antibodies
(Figure S3B).
Since neither homozygousArf deletion norArf repressor
overexpression was found in lung tumors from Dmp1+/+;
K-rasLA/+ mice, we hypothesized that the Dmp1 gene
might be deleted in some of these lung tumors. Quantita-
tive real-time PCR showed that 5 of 12 lung tumors from
Dmp1 wild-type mice showed single allelic deletion of
the Dmp1 gene (465, 381, 154, 395, and 205) (Figure 3C,
white bars). Interestingly, 5 of 8 (63%) p53 wild-type
lung tumors showed deletion of the Dmp1 gene, while
none of the p53 mutant lung tumors showed hemizygous
deletion of Dmp1 (356, 59, 208, and 844) (Figure 3C; p =
0.038, c2 = 4.29). The Dmp1 locus was selectively deleted
inK-rasLA lung tumors in most cases since the gram3 gene
located430 kb upstream of theDmp1 locus was deleted
in only one of 12 K-rasLA lung tumors and the abcb1 gene
located 430 kb downstream from the Dmp1 locus was
never deleted in any of the 12 lung tumors (Figure S4).
The Dmp1 gene was not deleted in any of the lung tumor
DNAs isolated from p53+/;K-rasLA or p53/;K-rasLA
mice, showing mutually exclusive inactivation of Dmp1
and p53 in K-rasLA lung tumors (Figure 3D). Collectively,
our data indicate that when lung carcinomas arise from
wild-type K-rasLA mice, the cells undergo either p53muta-
tion or Dmp1 deletion to inactivate the Arf-p53 pathway.
Loss of Heterozygosity and Promoter
Hypermethylation Analyses of hDMP1 in Human
Non-Small-Cell Lung Cancer
The hDMP1 gene is located on human chromosome 7q21,
a region which is often deleted in therapy-induced acute
leukemias and myelodysplastic syndromes (Bodner
et al., 1999). Whether the human DMP1 gene (hDMP1) is
inactivated in human carcinomas has never been inves-
tigated. We therefore extracted genomic DNA from
51 non-small-cell lung cancer samples (33 adenocarci-
nomas, 16 squamous cell carcinomas, and 2 adenosqua-
mous carcinomas) and studied LOH for hDMP1 with two
different sets of primers that amplify the dinucleotide re-
peats located at the 50 (92465, 34 kb from hDMP1) and386 Cancer Cell 12, 381–394, October 2007 ª2007 Elsevier Inc30 ends of the hDMP1 gene (198004, 28 kb from hDMP1;
Figure 4A). For INK4a/ARF LOH analysis, we designed
primers that amplify the repetitive sequences within 500
bps from human ARF Exon 1b (33647) and those that am-
plify the sequences between Exon 1b and Exon 1a (27251;
Figure 4B). There are at least 4 high-affinity hDMP1 bind-
ing sites in this region (Figure 4B, inverted red triangles).
For P53, two sets of primers were selected that amplify
the dinucleotide repeats located 26 kb 50 (158111) and
11 kb 30 (89737) of the P53 gene (Figure 4C). Two major
area peaks were quantified from paired samples (normal
tissue and lung cancer), and the qLOH values were calcu-
lated (see equation described in the Experimental Proce-
dures). When the qLOH values were more than 2.0 or
less than 0.5 with either one of the two sets of LOH
primers, the tumor sample was found to have LOH for
the locus (Figures 4 and 5). Typical cases of LOH positive
samples are shown in Figures 4D and 4E for hDMP1 (with
92465 and 198004 primer sets), Figures 4F and 4G for
INK4a/ARF (with 33647 and 27251), and Figures 4H and
4I for P53 (with 158111 and 89737). We also conducted
hDMP1, p14ARF, and p16INK4a promoter hypermethylation
assays (Figure 5; Figure S5). The sequences of primers for
LOH and promoter hypermethylation assays are shown in
Table S1.
With the 50 set of hDMP1 primers (92465), 14 of 42 cases
(33.3%) were positive for LOH; with the 30 set of hDMP1
primers (198004), 13 of 36 cases were positive (36.1%).
Seven of 29 cases (24.1%) were positive for LOH with
both of these hDMP1 primer sets (Figure 5). We then con-
ducted detailed mapping of the genomic locus on human
chromosome 7q21 deleted in human NSCLC with 5 other
sets of LOH primers (Figure 6A). We also conducted quan-
tification of the hDMP1 genomic DNA at exons 8 and 20 by
real-time PCR to supplement the LOH study (Figures 6A
and 6B). Interestingly, the genomic region deleted in
NSCLC was confined to the hDMP1/MGC4175 locus
(i.e., from 69164 to 259145) in 15 of 19 hDMP1 LOH(+)
cases (Figure 6B, 2000-3 was not included). Thus, the
hDMP1/MGC4175 locus was specifically targeted in
NSCLC samples although there were a small number of
cases that showed broader deletion, including the
hDMP1/MGC4175 locus.
Next we conducted hDMP1 promoter methylation as-
say by using enzymatically methylated human genomic
DNA as a positive control. We found only one case of
hDMP1 promoter hypermethylation (2000-3; Figure 5;
Figure S5). We then isolated RNAs from lung cancer sam-
ples from seven different patients in whom duplicate tu-
mor samples were available and conducted sequencing
of the hDMP1 cDNA. All of the seven samples expressed
the hDMP1 mRNA, but none of them, including those
which showed LOH for hDMP1 (1999-10, 2005-308, and
2005-522), showed mutations for hDMP1 (data not
shown). We then investigated if lung cancer cells had
splicing alterations for hDMP1 by real-time TaqMan PCR
in 11 samples that had been randomly chosen. However,
we could not detect any lung cancer-specific overexpres-
sion of the hDMP1b isoform that has dominant-negative.
Cancer Cell
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Analysis of the hDMP1, INK4a/ARF, and
P53 Loci in Human Non-Small-Cell Lung
Carcinomas
(A) Genomic locus of the hDMP1 gene. The two
different primer sets were designed to amplify
the dinucleotide repeat sequences located on
the 50 and 30 end of the hDMP1 gene. The non-
coding exons were colored silver and the cod-
ing exons were colored gold.
(B) Genomic structure of the human INK4a/
ARF locus. The two sets of PCR primers were
designed to detect the dinucleotide repeats
within 500 bps of Exon 1b (33647) and those
between Exon 1b and Exon 1a (27251). The in-
verted triangles shown in red indicate the loca-
tion of high-affinity hDMP1-binding sites.
(C) Genomic structure of the human P53 gene
and the location of the PCR primers used for
LOH analyses.
(D–I) Representative patterns of LOH for
hDMP1, INK4a/ARF, and P53 in human non-
small-cell lung carcinoma. Genomic DNA was
extracted from lung carcinomas and their nor-
mal counterparts, and PCR was conducted
with 6-FAM-labeled primers that amplify the di-
nucleotide repeats within (or close to) each lo-
cus. The area peaks of the PCR products were
quantitated by ABI 3700 DNA analyzer. The
qLOH values were determined through the following equation: qLOH = Area Peak 1/Area Peak 2 (normal tissue) divided by Area Peak 10/Area
Peak 20 (tumor tissue). The arrows indicate the peak that was lost in tumor cells. The sample was considered to have LOH when the value was
>2.0 or <0.5. (D) LOH analysis of NSCLC with 50 hDMP1 primer set, 92465. (E) LOH analysis of NSCLC with 30 hDMP1 primer set, 198004. (F)
LOH analysis with INK4a/ARF 50 probe, 33647. (G) LOH analysis with INK4a/ARF 30 probe, 27251. (H) LOH analysis with P53 50 158111 primers.
(I) LOH analysis with P53 30 89737 primers.effect on hDMP1a (Figure S6; Tschan et al., 2003). Thus,
hemizygous gene deletion was considered to be the major
mechanism of hDMP1 inactivation in NSCLC.
Mutually Exclusive Deletion of hDMP1
and INK4a/ARF, P53 in Human NSCLC
The 51 pairs of NSCLC samples were also studied for LOH
of INK4a/ARF and P53. With INK4a/ARF primers, 12 of 40
cases (30%) were positive for LOH or showed biallelic de-
letion with the 33647 primers, and 16 of 45 samples
(35.6%) were positive for LOH or showed biallelic deletion
with 27251 primers (Figures 4 and 5). Ten of 35 cases
(28.6%) showed LOH or homozygous deletion with both
sets of the INK4a/ARF probe. Promoter hypermethylation
was found in 3 cases (3/46, 6.5%) for p14ARF and 25 cases
(25/47, 53.2%) for p16INK4a, compatible with previous
reports from other groups (Meuwissen and Berns, 2005)
(Figure 5; Figure S5). Ten cases of the p16INK4a promoter
hypermethylation were observed simultaneously with
LOH of the locus (Figure 5). Three tumor samples showed
homozygous deletion of Exon 1b for p14ARF (2003-86,
2003-442, and 2003-246). Together, the results suggest
that these two genes behaved as classical tumor suppres-
sors in the NSCLC samples. Interestingly, 32 out of 34
cases showed mutually exclusive inactivation of the
hDMP1 and the INK4a/ARF loci (94.1%; 95% confidence
interval, 86.2% to 100%; p = 0.0035, c2 = 8.52 based on
mutually exclusive hypothesis) compatible with the clusterCaof hDMP1-binding sites throughout the INK4a/ARF locus
(Figure 4B). LOH of P53 was found in 30.4% (14/46) with
50 primers, 46.2% (18/39) with 30 primers, and 24.3% (9/
37) with both primers. Sequencing analysis of P53 cDNAs
from six lung cancer samples demonstrated the presence
of point mutations of P53 in LOH(+) samples (2005-308,
2005-391, 1995-95, and 2005-242), but not in LOH() sam-
ples (2005-522, 2005-346), indicating that both alleles of
P53 were inactivated in the lung cancer cells that showed
LOH for P53 (data not shown). Again, LOH of hDMP1 and
that of P53 tend not to overlap each other (Figure 5; 30/
35 = 85.7% exclusive; 95% confidence interval, 74.1% to
97.3%; p = 0.027, c2 = 4.88 based on mutually exclusive
hypothesis). On the other hand, inactivation of the INK4a/
ARF locus and that of the P53 locus was found to actually
occur more frequently together rather than mutually exclu-
sively (Figure 5; 14/27, 51.9% exclusive; 95% confidence
interval, 33.0% to 70.7%; p = 0.0045, c2 = 8.08 against mu-
tually exclusive hypothesis). We then genotyped NSCLC
samples for K-Ras mutation. Point mutations involving
codons 12 or 13 of K-Ras were found in 7 of 48 samples
analyzed (14.6%), and 3 of the 7 K-Ras mutations were
found in hDMP1 LOH(+) samples (2000-19, 2006-750,
and 2005-83; shown in bold ID in Figure 6). Taken together,
LOH of the hDMP1 gene was found in 35% of human
NSCLC, especially those that retain a wild-type INK4a/
ARF and/or P53 locus and15% of hDMP1 LOH occurred
simultaneously with K-Ras mutation.ncer Cell 12, 381–394, October 2007 ª2007 Elsevier Inc. 387
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Deletion of DMP1 in Lung CancerFigure 5. Summary of the Results for qLOH Values and Promoter Hypermethylation in 51 Cases of Human Non-Small-Cell Lung
Cancer
The positive results for LOH (qLOH > 2.0 or < 0.5) were shown in bold red characters. When one of the two markers (50 or 30) showed qLOH value >2.0
or <0.5, the sample was found to be positive for LOH for the tumor suppressor locus. Cases of mutually exclusive inactivation of hDMP1 and INK4a/
ARF or hDMP1 and P53 are shown ‘‘yes’’ in bold blue characters. Abbreviations: LC adeno, adenocarcinoma of the lung; LC squam, squamous cell
carcinoma of the lung; LC adenosq, adenosquamous carcinoma of the lung; hDMP1Met, humanDMP1 promoter hypermethylation;ARFMet, p14ARF
promoter hypermethylation; INK4a Met, p16INK4a promoter hypermethylation. Exclusive of DMP1 LOH, LOH of INK4a/ARF (or P53) not overlapping
with that of hDMP1 in the same sample. Del, homozygous deletion; single, LOH was not evaluated due to a single peak result; partial, weak promoter
methylation. ND, not determined. ND*, not determined due to positive signals from histologically normal tissue (Holst et al., 2003).Detection of the hDMP1 Protein in Human Lung
Cancer Samples and Growth Inhibition of Lung
Cancer Cell Lines by Activated Dmp1:ER
To investigate the consequences hemizygous of hDMP1
deletion in human NSCLC cells, formalin-fixed, paraffin-
embedded lung cancer sections were stained with
Dmp1-specific antibody, RAX (Mallakin et al., 2006;388 Cancer Cell 12, 381–394, October 2007 ª2007 Elsevier IncFigure S7). Strong signals were detectable in the nuclei
of P53 mutant NSCLC cell line H727, which was dramati-
cally downregulated by infecting the cells with hDMP1-
specific shRNA retroviruses (Figures S7A–S7C). Then we
randomly chose 9 hDMP1 LOH(+) and 8 hDMP1 LOH()
lung cancers and stained them with the antibody to
Dmp1. Positive nuclear staining (grade 3++ to 2+) was.
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Deletion of DMP1 in Lung CancerFigure 6. Detailed Mapping of the Chromosomal 7q21 Region Deleted in Human NSCLC
(A) Genomic structure of the human hDMP1 locus and the primers used for the LOH analyses. GRM3, glutamate receptor 3; KIAA1324L, KIAA1324-
like; MGC4175, Mammalian Gene Collection 4175; CROT, carnitine O-octanoyltransferase; ABCB4, ATP-binding cassette, subfamily B (MDR/TAP),
member 4; ABCB1, ATP-binding cassette, subfamily B (MDR/TAP), member 1.
(B) Summary of the qLOH and real-time PCR values with 9 different markers (7 LOH and 2 real-time PCR) in the 20 hDMP1 LOH(+) samples and 9
hDMP1 LOH() samples. The positive results for LOH (qLOH > 2.0 or < 0.5) are shown in bold red. In real-time PCR, the samples were found to
have hemizygous deletion of hDMP1 when the genomic DNA level was 0.25–0.65 (H.D. in bold red, DNA in the normal lung = 1.00). The borderline
cases (0.66–0.75) are shown in pink. Samples that showed point mutation forK-Ras at codon 12 or 13 are shown in bold ID. H.D., hemizygous deletion;
no del, no deletion as studied by genomic DNA real-time PCR; N.D., not done; single, single peak in LOH analysis. Note that there are only two genes at
the hDMP1 locus between markers 69164 and 251945 (hDMP1 and MGC4175), and this locus is selectively deleted in 15 of 19 NSCLC samples.obtained in 8 of 8 hDMP1 LOH() lung cancer samples
while the staining was very weak (grade 1+/) or nega-
tive (grade 0) in 7 of 9 hDMP1 LOH(+) lung cancers
(Figure S7H). In one case (2006-171) the hDMP1 signal
was negative, suggesting the complete inactivation of
the hDMP1 protein in lung cancer cells. Thus, our immu-
nohistochemistry results are quite consistent with those
of hDMP1 LOH analyses (p < 0.001).
We then studied if Dmp1 overexpression inhibits the
growth of human NSCLC cell lines with different geneticCabackgrounds of ARF and P53. In H460 cells with wild-
type ARF and P53, activation of Dmp1:ER with 4-hydrox-
ytamoxifen (4-HT) (Inoue et al., 1999) efficiently inhibited
the growth (Figure 7A, pink line). On the other hand, lung
cancer cell lines that lack INK4a/ARF (A549) or P53
(H1299, H358) proliferated exponentially even with activa-
tion of Dmp1:ER, although their growth was slightly slower
than control cells (Figures 7B–7D; pink lines, Dmp1:ER
virus-infected cells with 4-HT; blue lines, mock-infected
cells with 4-HT). Western analysis showed accumulationncer Cell 12, 381–394, October 2007 ª2007 Elsevier Inc. 389
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Deletion of DMP1 in Lung CancerFigure 7. Proliferation Assay of Human
Non-Small-Cell Lung Cancer Cell Lines
by Overexpressing Dmp1:ER
(A) H460; hDMP1+/, ARF+, p16del, P53+, Rb+
(B) H1299; hDMP1+, ARF+, p16Met, P53del,
Rb+ (C) A549; hDMP1+, ARFdel, p16del, P53+,
Rb+ (D) H358; hDMP1+, ARF+, p16Met, P53del,
Rb+. Pink lines show the growth curves of
Dmp1:ER virus-infected cells treated with 2
mM 4-HT; blue lines show those of mock-in-
fected cells with 4-HT (mean ± SEM). Activa-
tion of Dmp1:ER by 4-HT inhibited the growth
of H460 cells with wild-type ARF and P53,
but had little effects on other lung cancer cell
lines that showed deletion of ARF or P53. (E)
Western blotting analyses of H460 and H1299
cells expressing activated Dmp1:ER or empty
vector with specific antibodies to Dmp1,
p14ARF, p53, hDM2, and p21Cip1. The numbers
show hours after addition of 4-HT.of p14ARF, p53, and its target hDM2 and p21Cip1 in H460
cells where Dmp1:ER was activated with 4-HT (Figure 7E,
left panel). In H1299 cells, only p14ARF increased with
stimulation of Dmp1:ER (Figure 7E, right panel). Interest-
ingly, real-time PCR analysis showed that the hDMP1
gene was hemizygously deleted in H460 cells, but not in
other cell lines (data not shown). Together, the results
indicate that overexpression of activated Dmp1:ER effi-
ciently inhibits the growth of the human lung cancer cell
line that has wild-type ARF and P53.
DISCUSSION
It has now become clear that the DMP1 transcription fac-
tor is primarily involved in both human and murine lung
cancer. The hDMP1 gene is located on human chromo-
some 7q21, a locus often deleted in human malignancies
(Bieche et al., 1992; Kerr et al., 1996; Oriola et al., 2001).390 Cancer Cell 12, 381–394, October 2007 ª2007 Elsevier IncOne previous report showed that the hDMP1 locus was
lost in 9 out of 9 leukemic cells with chromosome 7q ab-
normalities as studied by FISH, regardless of the detailed
karyotype of leukemic cells (Bodner et al., 1999). How-
ever, it was difficult to point to the roles of hDMP1 in hu-
man 7q- leukemias since the probe contained sequences
of several other genes as well. In this study, we designed
unique primers that specifically amplify the repetitive se-
quences located within 35 kb of the hDMP1 gene. Thus,
the experimental results dependably reflected the events
occurring within the locus. With these probes, we could
detect the LOH of the hDMP1 locus in 35% of NSCLC
samples, the frequency of which was even close to that
of the INK4a/ARF or P53 locus of the same samples
(30%–45%). Our detailed analysis showed that the dele-
tion of chromosome 7q21 was limited to the hDMP1/
MGC4175 locus in more than 75% of the samples in
human NSCLC. Likewise, in K-rasLA lung tumors, the.
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than 90% of the cases (Figure S4). It was not possible to
distinguish the deletion of hDMP1 and that of MGC4175
by LOH analyses since these two genes are too closely lo-
cated. However, it is very unlikely that MGC4175 deletion
contributes to pulmonary carcinogenesis since it encodes
a mitochondrial protein that is associated with taxol- and
doxorubicin-resistant malignant phenotypes in human
cancer cell lines (Duan et al., 2004). Most importantly,
our current K-rasLA;Dmp1-knockout mice model clearly
points to the role of Dmp1-deletion in pulmonary carcino-
genesis since MGC4175 remains intact in the Dmp1-tar-
geting vector (Inoue et al., 2000). Thus, we speculate that
hDMP1 is the critical gene for suppression of pulmonary
carcinogenesis located on human chromosome 7q21.
Human DMP1 promoter hypermethylation was found
only in one of the 23 lung cancer samples we examined,
and none of them showed biallelic deletion of the
hDMP1 gene. The second hDMP1 allele was expressed
and not mutated in the tumor cells that showed LOH, al-
though there was one exceptional case where lung tumor
cells showed both LOH and promoter methylation for
hDMP1. Likewise, splicing alterations that result in the
overexpression of the dominant-negative hDMP1b iso-
form was not found in the 11 samples we have randomly
analyzed (Figure S6). Generally, promoter hypermethyla-
tion or point mutation of the second allele is a feature of
classical tumor suppressor genes and is very rare in
haplo-insufficient tumor suppressors, such as p27Kip1
(Chim et al., 2005; Kibel et al., 2001; for review see Herman
and Baylin, 2003). Thus, our data are consistent with our
hypothesis that hDMP1 may be haplo-insufficient for tu-
mor suppression in human lung cancer. On the other
hand, 3 of 40 NSCLC cases showed biallelic deletion of
ARF Exon 1b and 10 of 25 cases of p16INK4a promoter
methylation occurred simultaneously with LOH of the
INK4a/ARF locus (Figure 5), compatible with the concept
of INK4a/ARF being classical tumor suppressors.
Our data indicate that LOH of the hDMP1 gene and that
of the INK4a/ARF locus occurred in mutually exclusive
fashion in >90% of the cases (p < 0.01), although there
were two exceptional cases that showed inactivation of
both the hDMP1 and the INK4a/ARF loci. One possible ex-
planation is that the deletion or methylation of the INK4a/
ARF locus will result in the absence or modification of the
hDMP1-binding sites; thus, tumors that have inactivated
INK4a/ARF do not have to delete the hDMP1 gene at the
same time. Likewise, LOH of hDMP1 also occurred signif-
icantly less frequently in lung tumors that showed LOH for
P53 (p < 0.05). Interestingly, one of the four human non-
small-cell lung cancer cell lines (H460) showed hemizy-
gous deletion of hDMP1, where both ARF and P53 are
wild-type (Somasundaram et al., 1999) and K-Ras is mu-
tant. Activated Dmp1:ER efficiently induced p14ARF and
inhibited the growth of H460 cells while other lung cancer
cell lines with deletion of ARF (A549) or P53 (H1299, H358)
were resistant to Dmp1 overexpression. Consistent with
the human data, the Dmp1 gene was deleted only in
K-rasLA lung tumors with wild-type p53 but not in any ofCathe lung tumors from p53+/ or p53/;K-rasLA mice, sug-
gesting the mutually exclusive inactivation of Dmp1 and
p53 in K-rasLA lung tumors. Collectively, the DMP1 gene
is frequently deleted in lung tumors where the INK4a/
ARF locus and/or the P53 locus remains wild-type since
hDMP1, ARF, and P53 are in the same signaling pathway.
Although homozygous deletion of Arf was not observed
in any K-rasLA lung tumors, hemizygous deletion of Arf
was found in25% of lung tumors regardless of the geno-
type of Dmp1. Haploid insufficiency of p19Arf has been
reported in murine solid tumors only when p16Ink4a was
homozygously inactivated (Krimpenfort et al., 2001). How-
ever, inactivation of p16Ink4a by gene deletion or promoter
hypermethylation is rare in K-rasLA lung tumors (Johnson
et al., 2001; J. Sage, personal communication). Therefore,
it is unlikely that the hemizygous Arf deletion contributed
to lung tumorigenesis. If Arf does not contribute to K-rasLA
lung tumors, Dmp1 should be regulating the p53 activity
by a yet unknown mechanism. On the other hand,
p14ARF is apparently involved in human NSCLC either by
(1) biallelic deletion (2003-86, 2003-442, and 2003-246)
(Figure 5) or by (2) hemizygous deletion with simultaneous
biallelic inactivation of the p16INK4a locus (2000-96, 2003-
422, 2004-719, 2004-983, 1999-95, and 2006-172).
K-rasLA lung tumors are different from Em-Myc lympho-
mas in that biallelic Arf deletion or Mdm2 overexpression
was not found in any tumors regardless of the genotype
of Dmp1 (Inoue et al., 2001). None of the Ink4a/Arf modu-
lators, such as Bmi1, Twist, Tbx2/3, and Pokemon were
overexpressed in K-rasLA lung tumors, ruling out the pos-
sibility of the involvement of these Ink4a/Arf modulators
for K-ras-induced tumor formation. p53 mutation was
less frequent in lung tumors from Dmp1+/, Dmp1/;
K-rasLAmice, thus,Dmp1deletions andp53mutations might
have similar effects. In fact, we have found that tumors
that showed deletion of Dmp1 tend to show the pheno-
type of adenocarcinomas (5/7, 71%; the number includes
two other cases of Dmp1 deletion that were not shown in
Figure 3). All the lung tumors that showed mutation of p53
were adenocarcinomas (4/4, 100%). On the other hand,
lung tumors that did not show Dmp1 or p53 alterations
were mostly adenomas, and there was only one case of
adenocarcinoma in this group (1/5, 20%). This phenotypic
difference was statistically significant (p = 0.036 for Dmp1
deletion, p = 0.016 for p53 mutation). Thus, deletions of
Dmp1 or mutations of p53 are frequently associated with
malignant phenotypes of K-rasLA lung tumors.
Dmp1 showed typical haploid insufficiency in suppres-
sion of K-rasLA lung cancers, especially in K-rasLA2/+
tumors. Although many other tumor suppressor genes
have now been reported to show haploid-insufficiency to
some extent, this level of strong haploid insufficiency
was observed only in p27Kip1 and Dmp1 (reviewed in
Payne and Kemp, 2006; Quon and Berns, 2001). In the
case of p27Kip1, it was explained that complete loss of
p27Kip1 results in decreased assembly of cyclin D1 and
Cdk4, especially in mammary epithelial cells, thus,
MMTV-neu-induced breast cancer was not accelerated
in a p27Kip1/ background (Muraoka et al., 2002).ncer Cell 12, 381–394, October 2007 ª2007 Elsevier Inc. 391
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sufficiency of Dmp1 remain to be determined, apparently
one copy loss of Dmp1 is enough to inactivate the p53
pathway in K-ras as well as in Em-Myc-induced tumor for-
mation (Figure 3A in this study; Inoue et al., 2001).
In conclusion, we have demonstrated that the Dmp1
(hDMP1) gene is hemizygously deleted in a significant per-
centage of murine and human non-small-cell lung carcino-
mas, especially those which retained the intact Arf-p53
pathway. Thus, DMP1 is principally involved in pulmonary
carcinogenesis. Dmp1 showed haploid insufficiency in
K-rasLA murine lung tumors, and our data with lung cancer
patients’ samples are compatible with haploid insuffi-
ciency of hDMP1 in NSCLC. Since hDMP1 LOH (+) lung
cancer cells retain one allele of the hDMP1 locus, this
gene might be a promising target for future drug develop-
ment.
EXPERIMENTAL PROCEDURES
Creation of Dmp1+/, Dmp1/;K-rasLA/+ Mice
Dmp1-heterozygous females were backcrossed to the same C57BL/6
male for more than six generations to obtain Dmp1+/ mice that were
>98% C57BL/6 background overall. The mouse Dmp1 gene is local-
ized on chromosome 5. All the seven markers on mouse chromosome
5 had been replaced with the C57BL/6 markers at G6. One male
K-rasLA1/+ orK-rasLA2/+ mouse was crossed with twoDmp1+/ females
to obtain Dmp1+/;K-rasLA1/+ or K-rasLA2/+ mice. Then these Dmp1+/;
K-rasLA/+ transgenic mice were further crossed with Dmp1+/ mice to
obtain more than 25 mice with each genetic background. Mice were
observed daily and were euthanized when they showed any signs of
tumor formation. Mice were maintained in accordance with the Guide
for the Care and Use of Laboratory Animals.
Statistical Analyses
Statistical differences of survival in Dmp1+/+, Dmp1+/, and Dmp1/;
K-rasLA1/+ or K-rasLA2/+ mice were analyzed by XLSTAT-Life soft-
ware (Addinsoft, New York, NY). Mann-Whitney tests (two-sided)
were used to generate the p values (significance level, a = 0.05). For
each comparison of LOH, we performed a 1 degree of freedom test
to determine whether the LOH of hDMP1, INK4a/ARF, and P53 in
NSCLC samples were more likely to occur mutually exclusively or to-
gether. To do this, three separate chi-square tests were performed—
one for each pair of data (i.e., hDMP1 and INK4a/ARF, hDMP1 and
P53, and INK4a/ARF and P53). In these analyses, we examined the ex-
pected cell count versus the observed cell count in order to determine
whether there was evidence of mutual exclusivity or not (evidence of
mutual exclusivity is supported when the off-diagonal elements of
the 2 3 2 table have higher observed counts than expected, whereas
mutual exclusivity is not supported if the main diagonal cells of the 23
2 table have higher observed counts than expected). In addition to per-
forming chi-square tests, we estimate 95% confidence intervals for bi-
nomial proportions (using a normal approximation). These intervals
were calculated using data where at least one of the two markers
showed LOH (shown in bold red in Figure 5) and we estimated the
probability that co-occurrence does not happen given that at least
one marker has occurred. Unpaired Student’s t tests were conducted
for the analyses of number and size of K-rasLA lung tumors as well as to
demonstrate the difference of intensity of hDMP1 signals in immuno-
histochemistry.
Human Lung Cancer Samples
Fifty-one pairs of frozen human lung cancer tissues (33 cases of ade-
nocarcinoma, 16 cases of squamous cell carcinoma, and 2 cases of
adenosquamous carcinoma) and their normal counterparts were ob-392 Cancer Cell 12, 381–394, October 2007 ª2007 Elsevier Inc.tained from the Tissue Procurement Core Facility at the Wake Forest
University Comprehensive Cancer Center. The samples had already
been resected from patients with informed consent and had been
stored in liquid nitrogen. The samples do not contain any subject iden-
tifiers. The human protocol had been approved by the Institutional
Review Board.
Loss of Heterozygosity and Sequencing Analyses of Human
Lung Cancer Specimen
Two sets of markers for microsatellite analysis of hDMP1 (92465,
198004), two sets of markers for INK4a/ARF (33647, 27251), and two
sets of markers for P53 (158111, 89737) were selected by using the
software at http://www.gramene.org (Ware et al., 2002) (Figures 4A–
4C). These markers were chosen because they are polymorphic be-
tween individuals in more than 60% of the cases. For detailed mapping
of the region deleted in human NSCLC, 4 other sets of primers were
designed by ourselves (B-Actin, 69164, 251945, and ABCB1) (Fig-
ure 6A, Table S1). D7S644 sequences were obtained from the NCBI.
The forward primer of each pair was labeled on the 50 end with the
fluorescent dye FAM (Operon Technologies, Huntsville, AL), and
PCR amplification was performed with DNA isolated from the tumor
and normal tissues. PCR products were visualized on a 1.2% agarose
gel. Genotypes were identified by peak analysis of the fluorescent sig-
nal detected on an ABI 3700 DNA analyzer (Applied Biosystems). The
qLOH values were determined through the following equation. qLOH =
Area Peak 1/Area Peak 2 (normal tissue) divided by Area Peak 10/Area
Peak 20 (tumor tissue). LOH was assessed if the qLOH value was found
to be >2.0 or <0.5 (So et al., 2004). Each sample was found to be pos-
itive for LOH of the locus when the qLOH values were >2.0 or <0.5 in
one of the two sets of primers. When one of the two sets of LOH
primers showed a single peak, LOH was determined by the other
set. Whenever duplicate samples were available, total RNA was
extracted from lung cancer tissues by using RNAlater-ICE (Ambion,
Applied Biosystems) and TRIzol (Invitrogen, Carlsbad, CA), and RT-PCR
was conducted with PfuUltra Hotstart DNA polymerase (Stratagene,
La Jolla, CA).
Other Experimental Procedures
Other Experimental Procedures are described in the Supplemental
Data available with this article online.
Supplemental Data
The Supplemental Data include Supplemental Experimental Proce-
dures, one supplemental table, and seven supplemental figures and
can be found with this article online at http://www.cancercell.org/
cgi/content/full/12/4/381/DC1/.
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